Skip to main content
. 2009 Jul 17;284(38):25984–25992. doi: 10.1074/jbc.M109.016808

FIGURE 3.

FIGURE 3.

Treatment with a CAR agonist inhibited lipogenesis, VLDL-triglyceride secretion, and gluconeogenesis. A, liver, skeletal muscle, BAT, and WAT were measured for the mRNA expression of genes involved in lipogenesis by real time PCR analysis. Male C57BL/6J mice were HFD-fed and drug-treated for 1 week. n = 4 for each group. B, Oil-red O staining of liver sections from male C57BL/6J mice fed with HFD and treated with TCPOBOP for 8 weeks. C and D, gross appearance (C) and hematoxylin/eosin staining of abdominal WAT and BAT of mice described in B. E, VLDL-triglyceride secretion rate in male C57BL/6J mice treated with vehicle or TCPOBOP for 8 weeks. Mice were fasted for 4 h before receiving an intravenous injection of tyloxapol (500 mg/kg body weight). Blood was sampled at 1, 2, and 4 h and measured for serum concentrations of triglycerides. n = 4 for each group. F, liver mRNA expression of genes involved in gluconeogenesis was measured by real time PCR analysis. Mice were the same as those described in A. *, p < 0.05; **, p < 0.01, compared with the vehicle group.